Long-term complications of COVID-19

AD Desai, M Lavelle… - American Journal of …, 2022 - journals.physiology.org
SARS-CoV-2 has rapidly spread across the globe and infected hundreds of millions of
people worldwide. As our experience with this virus continues to grow, our understanding of …

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

A Bonaventura, A Vecchié, L Dagna… - Nature Reviews …, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe …

[HTML][HTML] Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3 …

F Ader, M Bouscambert-Duchamp, M Hites… - The Lancet infectious …, 2022 - thelancet.com
Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid …

M Sholzberg, GH Tang, H Rahhal, M AlHamzah… - bmj, 2021 - bmj.com
Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …

Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among …

S Mazloomzadeh, S Khaleghparast, B Ghadrdoost… - Jama, 2021 - jamanetwork.com
Importance Thrombotic events are commonly reported in critically ill patients with COVID-19.
Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate …

Risk factors for severe and critically ill COVID‐19 patients: a review

Y Gao, M Ding, X Dong, J Zhang, A Kursat Azkur… - Allergy, 2021 - Wiley Online Library
The pandemic of coronavirus disease 2019 (COVID‐19), caused by the severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused an unprecedented global …

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

A Cuker, EK Tseng, R Nieuwlaat… - Blood …, 2021 - ashpublications.org
Background: Coronavirus disease 2019 (COVID-19)–related critical illness and acute illness
are associated with a risk of venous thromboembolism (VTE). Objective: These evidence …

SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19

S Zhang, Y Liu, X Wang, L Yang, H Li, Y Wang… - Journal of hematology & …, 2020 - Springer
Background Critically ill patients diagnosed with COVID-19 may develop a pro-thrombotic
state that places them at a dramatically increased lethal risk. Although platelet activation is …

Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update

W Alhazzani, L Evans, F Alshamsi, MH Møller… - Critical care …, 2021 - journals.lww.com
BACKGROUND: The coronavirus disease 2019 pandemic continues to affect millions
worldwide. Given the rapidly growing evidence base, we implemented a living guideline …

COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

M Nishiga, DW Wang, Y Han, DB Lewis… - Nature Reviews …, 2020 - nature.com
Abstract Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global …